
I-Mab IMAB
Quarterly report 2025-Q2
added 01-31-2026
I-Mab Depreciation & Amortization 2011-2026 | IMAB
Annual Depreciation & Amortization I-Mab
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 23.9 M | 25.3 M | 13.8 M | 12.7 M | 9.8 M | 6.7 M | 1.6 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25.3 M | 1.6 M | 13.4 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | ||
|
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
ANI Pharmaceuticals
ANIP
|
67.7 M | $ 81.6 | -0.49 % | $ 1.58 B | ||
|
Amgen
AMGN
|
5.59 B | $ 342.65 | -0.08 % | $ 184 B | ||
|
Adagene
ADAG
|
723 K | $ 2.75 | -5.5 % | $ 155 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Aytu BioScience
AYTU
|
5.38 M | $ 2.63 | 1.74 % | $ 16.5 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
PainReform Ltd.
PRFX
|
7 K | $ 0.68 | -4.45 % | $ 308 K | ||
|
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Aptose Biosciences
APTO
|
32 K | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | ||
|
Biogen
BIIB
|
673 M | $ 178.24 | 1.2 % | $ 26 B | ||
|
Brickell Biotech
BBI
|
41 K | - | -5.38 % | $ 6.06 M | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
Beam Therapeutics
BEAM
|
21.9 M | $ 27.94 | -4.61 % | $ 2.3 B | ||
|
Athira Pharma
ATHA
|
970 K | - | - | $ 269 M | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
22.2 M | $ 70.74 | 2.34 % | $ 9.46 B | ||
|
CASI Pharmaceuticals
CASI
|
468 K | $ 0.99 | -0.01 % | $ 135 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
131 K | - | -10.17 % | $ 12.2 K | ||
|
Catalyst Biosciences
CBIO
|
1.07 M | $ 9.63 | -5.08 % | $ 634 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
11 K | - | -9.72 % | $ 5.89 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
9.45 M | - | -15.15 % | $ 60.3 M | ||
|
Berkeley Lights
BLI
|
9 M | - | -7.31 % | $ 87 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 K | $ 4.05 | -1.22 % | $ 8.81 B | ||
|
Amneal Pharmaceuticals
AMRX
|
62.6 M | $ 13.65 | -3.3 % | $ 4.22 B | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Cerus Corporation
CERS
|
1.86 M | $ 2.32 | -0.22 % | $ 428 M | ||
|
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
398 K | - | 4.14 % | $ 49.1 M |